Contineum Therapeutics (CTNM) Stock Forecast: StockMap's 2-Week Call
CTNM stock forecast: StockMap's model leans Underperform on Contineum Therapeutics for the two weeks after the Nov 19 close, toward CTNM trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 5 two-week windows on CTNM since Sep 4; by chance, a call on the same dates was right 60% of the time.
Contineum Therapeutics last closed at $9.04, -2.16% on the session.
Against the IVW growth benchmark the position is +0.17% over the forecast window.
Contineum Therapeutics' market cap is $354.98M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -39 (too close to call).
Where CTNM sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
41 daily calls for CTNM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Contineum Therapeutics in the 25th percentile on return on equity, where 100 is best.
Contineum Therapeutics is classified under Health Care / Pharmaceuticals.
StockMap tracks Contineum Therapeutics as the 80th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Contineum Therapeutics ranks 88th of 153 in the group, against a group median of -0.36.